Bolt Biotherapeutics’ (BOLT) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a report released on Wednesday,Benzinga reports. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.57) EPS, FY2025 earnings at ($0.94) EPS and FY2026 earnings at ($0.74) EPS.

Bolt Biotherapeutics Stock Down 9.1 %

Shares of BOLT opened at $0.57 on Wednesday. Bolt Biotherapeutics has a 52-week low of $0.55 and a 52-week high of $1.56. The company has a quick ratio of 4.28, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The stock has a fifty day simple moving average of $0.64 and a two-hundred day simple moving average of $0.73. The company has a market capitalization of $21.64 million, a PE ratio of -0.33 and a beta of 0.92.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. The firm had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $1.02 million. As a group, equities analysts forecast that Bolt Biotherapeutics will post -1.52 EPS for the current year.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. acquired a new position in Bolt Biotherapeutics in the second quarter valued at about $26,000. Acuitas Investments LLC raised its stake in shares of Bolt Biotherapeutics by 21.7% in the 2nd quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after acquiring an additional 112,555 shares during the period. Finally, FMR LLC lifted its holdings in shares of Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after acquiring an additional 28,773 shares during the last quarter. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.